Retrospective Study Of SOX Regimen And FOLFOX6 Regimen In Neoadjuvant Therapy Of Gastric Cancer

Objective:The SOX regimen and FOLFOX6 regimen are currently widely used in neoadjuvant chemotherapy for locally advanced gastric cancer.In order to evaluate the short-term efficacy of the two neoadjuvant chemotherapy regimens in patients with operable gastric cancer.We retrospectively reviewed the two neoadjuvant chemotherapy regimens for gastric cancer patients from January 2016 to January 2018.Methods:A total of 54 patients were enrolled in this retrospective cohort study.They were given either SOX(n=24)or FOLFOX6(n=30)before the radical D2 gastrectomy for gastric cancer.The short-term efficacy of chemotherapy,lymph node metastasis,R0 resection rate,changes of tumor markers,adverse reactions,and surgical complications of the two groups were compared.Results:The two groups were well-matched.One patient in FOLFOX 6 group experienced rapid tumor progression and have to give up the surgery.The other 53 patients received D2 radical operation.SOX had a slight advantage over FOLFOX6 in the efficiency of chemotherapy(50% vs 40% P = 0.462).There was no significant difference in R0 resection rate(100% vs 96.55% P = 0.358).However the SOX group has a lower lymph node metastases rates in N2(37.5% vs 66.7% P=0.033)?The main Side effects of the twochemotherapy regimens included nausea,vomiting,diarrhea,neutropenia and liver function damage.The operative complications included infection,anastomotic leakage,gastrointestinal motility disorder and liver function damage.Changes in tumor markers were also observed.There was no significant difference between groups.Conclusion:SOX regimen was better than FOLFOX6 regimen in controlling metastatic lymph nodes,suggesting that SOX regimen might have better survival benefits.There was no significant difference in R0 resection rate,chemotherapeutic efficacy,neoadjuvant-related adverse reactions and postoperative complications between the two groups.